A comprehensive clinical investigation spearheaded by Tufts University researcher Bess Dawson-Hughes and her associates has revealed that vitamin D supplementation conferred a reduced risk of diabetes solely in individuals possessing specific genetic predispositions, indicating a potential shift towards individualized preventative strategies.
Dawson-Hughes and colleagues determined that prediabetic adults exhibiting particular variations in their vitamin D receptor gene experienced a 19% diminished likelihood of developing diabetes when administered a substantial daily dosage of vitamin D.
Dr. Dawson-Hughes along with her co-authors meticulously examined data derived from the D2d study, a multi-center, randomized, double-blind, placebo-controlled clinical trial that was conducted between October 1, 2013, and November 28, 2018.
The foundational objective of the original trial was to ascertain whether a daily regimen of 4,000 units of vitamin D, in comparison to a placebo, could mitigate the incidence of diabetes in over 2,000 U.S. adults diagnosed with prediabetes, a demographic identified as being at particularly elevated risk.
Nonetheless, the aggregate data did not demonstrate a statistically significant attenuation of diabetes risk across the entire participant cohort.
“Yet, the findings from the D2d study prompted a critical inquiry: could vitamin D still offer therapeutic benefits to certain individuals?” Dr. Dawson-Hughes posited.
“Diabetes is associated with a multitude of severe complications that manifest insidiously over extended periods.”
“If we possess the capacity to postpone the duration an individual lives with diabetes, we can potentially avert some of these detrimental sequelae or diminish their intensity.”
Through a prior analytical undertaking, the D2d research cadre established that blood concentrations of 25-hydroxyvitamin D ranging from 40 to 50 ng/mL, or higher, correlated with considerable and progressively amplified reductions in the participants’ susceptibility to developing diabetes.
Vitamin D circulating within the bloodstream undergoes conversion into its biologically active metabolite within the body prior to its engagement with the vitamin D receptor, a protein crucial for mediating cellular responsiveness to the vitamin.
The investigators hypothesized that genetic disparities within this receptor might elucidate the differential responses observed among individuals receiving vitamin D supplementation.
The insulin-secreting pancreatic beta cells are equipped with vitamin D receptors, suggesting a potential role for vitamin D in modulating insulin secretion and glycemic regulation.
For their subsequent investigation, the research scientists meticulously analyzed genetic information from 2,098 participants in the trial who had provided consent for DNA analysis, categorizing them into two distinct groups: those who appeared to derive benefit from vitamin D supplementation and those who did not.
Subsequently, the researchers conducted a comparative evaluation of response rates across patient subgroups stratified by three prevalent variations within the vitamin D receptor gene.
This detailed analysis brought to light that adults carrying the AA genotype of the ApaI vitamin D receptor gene — constituting approximately 30% of the study population — did not exhibit any significant response to daily high-dose vitamin D treatment when contrasted with the placebo group.
Conversely, the analysis indicated that the identical treatment regimen conferred a statistically significant reduction in the incidence of diabetes among adults possessing the AC or CC genotypes of the vitamin D receptor gene, relative to their placebo-receiving counterparts.
“These revelations potentially signify a pivotal advancement towards formulating a personalized strategy for mitigating the risk of developing type 2 diabetes in high-risk adult populations,” remarked Professor Anastassios Pittas of Tufts University School of Medicine.
“A key factor contributing to vitamin D’s appeal as a prospective preventative agent is its affordability, widespread accessibility, and ease of administration.”
The authors issued a cautionary note, emphasizing that these findings do not advocate for individuals to self-administer high doses of vitamin D for diabetes prevention.
Current established guidelines recommend a daily intake of 600 IU for individuals aged 1 to 70 years and 800 IU daily for those exceeding the age of 70.
Excessive vitamin D consumption can be detrimental and has been associated with an elevated risk of falls and fractures among the elderly population.
Additional research is imperative to gain a more profound understanding of which specific individuals might stand to benefit from an increased daily dosage.
“Our findings suggest that we may, in the future, be capable of identifying which prediabetic patients are most amenable to benefiting from supplementary vitamin D,” Dr. Dawson-Hughes stated.
“In principle, this could be facilitated by a singular, relatively low-cost genetic assay.”
The corroborating findings have been published in the esteemed journal JAMA Network Open.
_____
Bess Dawson-Hughes et al. 2026. Vitamin D Receptor Polymorphisms and the Effect of Vitamin D Supplementation on Diabetes Risk among Adults with Prediabetes. JAMA Netw Open 9 (4): e267332; doi: 10.1001/jamanetworkopen.2026.7332
